PipelineReview.com. Biopharmaceutical News & Clinical Trials
WEBOncoC4 Announces First Patient Dosed in Phase 1 Trial for Novel SIGLEC10 Immune Checkpoint Inhibitor ONC-841 for Solid Tumors. More news. Get the latest biopharma news, clinical trial updates, and industry insights at PipelineReview.com. Discover innovative therapies and regulatory news.
All news - Pipelinereview
WEB2 days ago · PipelineReview.com is powered by La Merie Business Intelligence For immediate assistance, please call us during business hours: Mon-Fri 10:00am - 05:00pm; GMT+01 La Merie Publishing - Ulrich Martin Veinat Puigsec - Can Magí s/n | 17862 Vallfogona de Ripollès | Spain | T +34-87-200 1365 | Email [email protected]
GSK Announces Positive Topline Data on Co-Administration of …
WEB3 hours ago · These data advance the science of co-administration of recommended adult vaccines. PHILADELPHIA, PA, USA I September 18, 2024 I GSK plc (LSE/NYSE: GSK) today announced positive topline data from the phase 3 trial in adults 50 years and older evaluating the immunogenicity, reactogenicity and safety of AREXVY (Respiratory Syncytial Virus Vaccine ...
I-Mab Presents Updated Phase 1 Givastomig Data at ESMO 2024
WEB9 hours ago · About Givastomig. Givastomig (TJ033721 / ABL111) is a bispecific antibody targeting Claudin 18.2-positive tumor cells. It conditionally activates T cells in the tumor microenvironment where Claudin 18.2 is expressed using 4-1BB. Givastomig appears to maintain a strong tumor binding property and anti-tumor activity, attributable to …
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) Plus …
WEB3 hours ago · Custom Report. La Merie Publishing offers the service of preparing customized reports tailored to the needs and specifications of the customer. We conduct scientific & medical literature evaluations for clients of the biopharmaceutical industry within the scope of our expertise.
Fasenra approved in the US for eosinophilic granulomatosis with ...
WEB9 hours ago · 130,00€. New indication supported by the MANDARA trial which showed nearly 60% of patients achieved remission and 41% of patients fully stopped taking oral corticosteroids. LONDON, UK I September 18, 2024 I AstraZeneca’s Fasenra (benralizumab) has been approved in the US for the treatment of adult patients with eosinophilic granulomatosis ...
FDA approves Novartis Kisqali® to reduce risk of recurrence in …
WEB9 hours ago · Broad indication in HR+/HER2- stage II and III early breast cancer (EBC) at high risk of recurrence approximately doubles population eligible for CDK4/6 inhibitor adjuvant therapy 1,2; Kisqali ® (ribociclib) significantly reduced the risk of recurrence by 25% vs. endocrine therapy (ET) alone; consistent benefit and a well-tolerated safety profile seen across all sub-groups in pivotal Phase ...
Ten-Year Data for Merck’s KEYTRUDA® (pembrolizumab) …
WEB2 days ago · Custom Report. La Merie Publishing offers the service of preparing customized reports tailored to the needs and specifications of the customer. We conduct scientific & medical literature evaluations for clients of the biopharmaceutical industry within the scope of our expertise.
RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE
WEBAug 21, 2024 · RYBREVANT ® plus LAZCLUZE™ is the first and only chemotherapy-free regimen showing superior progression-free survival versus osimertinib. Following Priority Review, approval is based on Phase 3 MARIPOSA results showing RYBREVANT ® plus LAZCLUZE™ reduced the risk of disease progression or death by 30 percent versus osimertinib, with a nine-month-longer median duration of response
European Commission Approves Astellas' PADCEV™ (enfortumab …
WEBAug 28, 2024 · Antibodies. European Commission Approves Astellas’ PADCEV™ (enfortumab vedotin) in Combination with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Advanced Urothelial Cancer